Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + ezetimibe + evolocumab
- Development stage
- Unknown
- Lead developer
- CHU de Québec-Université Laval
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This therapeutic combination, being investigated by CHU de Quebec-Universite Laval, involves the simultaneous administration of three cholesterol-lowering agents—atorvastatin, ezetimibe, and evolocumab—in conjunction with standard-of-care FOLFIRINOX chemotherapy. The regimen is specifically designed for patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The biological rationale is based on the high cholesterol requirements of pancreatic cancer cells for growth, membrane synthesis, and metastasis. By inhibiting HMG-CoA reductase (atorvastatin), blocking intestinal cholesterol absorption via NPC1L1 (ezetimibe), and reducing LDL receptor degradation through PCSK9 inhibition (evolocumab), the combination aims to induce a profound systemic and cellular cholesterol shortage. This metabolic reprogramming is intended to starve the tumor cells, inhibit their progression, and potentially sensitize them to the cytotoxic effects of chemotherapy.
- Brand names
- RepathaLipitorZetia
- Other names
- Cholesterol metabolism disruptionCHLOE pancreas regimenAtorvastatin, Ezetimibe and Evolocumab combination
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on atorvastatin + ezetimibe + evolocumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + ezetimibe + evolocumab.